Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Passage Bio, Inc. (PASG) announced that its CEO will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The event will be live webcasted and available for replay on the company's website. The focus of the company is on genetic medicines for neurodegenerative diseases.
01/31/2024 - 07:30 AM
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:00 a.m. ET.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com . A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com .
For further information, please contact:
Passage Bio Investors:mnafus@passagebio.com
Passage Bio Media:MikeBeyer@sambrown.com
When will the CEO of Passage Bio, Inc. participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference?
The CEO will participate on Thursday, February 8, 2024 at 10:00 a.m. ET.
Where can I watch the live webcast of the event?
The live webcast will be available on the Investors & Media section of Passage Bio's website at investors.passagebio.com.
How long will the replay of the presentation be available?
The replay will be available for 30 days following the event.
What is the focus of Passage Bio, Inc.?
The company is focused on genetic medicines for neurodegenerative diseases.
PASG Rankings
#4610 Ranked by Stock Gains
PASG Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
About PASG
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
